Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy?

Core Insights - Praxis Precision Medicines, Inc. (PRAX) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended September 2025 [1][3] - The consensus EPS estimate for the upcoming report is a loss of $3.45 per share, reflecting a 25.5% decrease year-over-year, while revenues are expected to be $0.33 million, up 10% from the previous year [3] Earnings Expectations - The earnings report could lead to a stock price increase if the actual results exceed expectations; conversely, missing estimates may result in a stock price decline [2] - The consensus EPS estimate has been revised down by 0.5% over the last 30 days, indicating a reassessment by analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Praxis Precision Medicines is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +5.35%, suggesting a bullish outlook from analysts [12] - The stock currently holds a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Praxis Precision Medicines was expected to post a loss of $3.4 per share but actually reported a loss of -$3.31, achieving a surprise of +2.65% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - PTC Therapeutics (PTCT), another company in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $1.19 per share for the same quarter, which represents a year-over-year increase of 14.4% [18] - PTC Therapeutics has an Earnings ESP of +5.75% and a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [20]